Kalaris Therapeutics, Inc.
KLRS
$8.52
-$0.29-3.29%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/17/2026
-
TipRanks Financial Blog
3/17/2026
-
TipRanks Financial Blog
3/17/2026
-
The Fly
3/17/2026
-
Globe Newswire
3/17/2026
-
Ticker Report
3/15/2026
-
MarketBeat
3/14/2026
-
Tickeron - Technical Analysis
3/12/2026
-
Tickeron - Stocks
3/10/2026
-
Ticker Report
3/10/2026
-
Tickeron - Technical Analysis
3/9/2026
-
TipRanks Financial Blog
3/8/2026
-
MarketBeat
3/7/2026
-
MarketBeat
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Tickeron - Stocks
3/5/2026
-
Tickeron - Technical Analysis
3/5/2026
-
Tickeron - Technical Analysis
3/4/2026
-
Tickeron - Stocks
2/21/2026
-
MarketBeat
2/20/2026
-
Tickeron - Stocks
Kalaris Therapeutics (KLRS, $10.34) price may drop as it broke higher Bollinger Band on Feb 18, 2026
2/19/2026
-
Tickeron - Stocks
2/19/2026
-
Tickeron - Stocks
Kalaris Therapeutics (KLRS, $10.34) price moved above its 50-day Moving Average on February 18, 2026
2/19/2026
-
Tickeron - Stocks
2/19/2026
-
Tickeron - Stocks
2/18/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
(est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
Address
628 Middlefield Road
Palo Alto, CA 94301
Palo Alto, CA 94301
Country
Year Founded
Business Description
Sector
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was...
more